Fast Market Research

Now Available: Fetzima (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Recently published research from GlobalData, "Fetzima (Major Depressive Disorder) - Forecast and Market Analysis to 2023", is now available at Fast Market Research

 

Boston, MA -- (SBWIRE) -- 06/20/2014 -- Fetzima (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Summary

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.

Fetzima (levomilnacipran) is an SNRI indicated for the treatment of MDD and is only available in the US. It gained FDA approval in July 2013 and was launched in December 2013. The product was developed by Forest (Actavis) following a partnership with Pierre Fabre. According to this agreement, Forest Laboratories is responsible for the clinical development and commercialization of Fetzima in the US and Canada, while Pierre Fabre is responsible for manufacturing and supplying the active pharmaceutical ingredient.

View Full Report Details and Table of Contents

Scope

- Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Fetzima including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Fetzima for the US from 2013 to 2023.
- Sales information covered for the US.

Reasons to Get This Report

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Fetzima performance
- Obtain sales forecast for Fetzima from 2013-2023 in the US.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- PharmaPoint: Major Depressive Disorder - US Drug Forecast and Market Analysis to 2023
- PharmaPoint: Major Depressive Disorder - 5EU Drug Forecast and Market Analysis to 2023
- PharmaPoint: Major Depressive Disorder - Australia Drug Forecast and Market Analysis to 2023
- PharmaPoint: Major Depressive Disorder - Japan Drug Forecast and Market Analysis to 2023
- Brexpiprazole (Major Depressive Disorder) - Forecast and Market Analysis to 2023
- Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023
- GLYX-13 (Major Depressive Disorder) - Forecast and Market Analysis to 2023
- ALKS-5461 (Major Depressive Disorder) - Forecast and Market Analysis to 2023
- Amitifadine (Major Depressive Disorder) - Forecast and Market Analysis to 2023
- Tedatioxetine (Major Depressive Disorder) - Forecast and Market Analysis to 2023